Skull base osteomyelitis by Pandoraea apista: An unusual pathogen at unusual location - A case report

Ninad Ramesh Patil1, Manjul Tripathi1, Kshitij Charaya2

  • 1Department of Neurosurgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Abstract

Insights

This study details the first reported case of central nervous system infection caused by Pandoraea apista, a bacterium typically found in cystic fibrosis patients. Early diagnosis and antibiotic treatment led to successful recovery, highlighting a rare opportunistic infection.

Area of Science:

  • Infectious Diseases
  • Neurology
  • Microbiology

Background:

  • Pandoraea apista is commonly associated with respiratory tract infections in cystic fibrosis (CF) patients.
  • Intracranial infections by P. apista are exceptionally rare, with no prior documented cases of central nervous system (CNS) involvement.

Observation:

  • A 67-year-old male presented with symptoms indicative of skull base osteomyelitis, including earache and hearing loss.
  • Radiological imaging revealed soft tissue extension from the middle cranial fossa to the infratemporal fossa.
  • Matrix-assisted laser desorption ionization-time-of-flight mass spectrometry identified P. apista in a sample from the affected area.

Findings:

  • This case represents the first documented instance of P. apista causing central nervous system infection, specifically skull base osteomyelitis.
  • The patient showed significant clinicoradiologic improvement following targeted antibiotic therapy.
  • Diagnosis was aided by matrix-assisted laser desorption ionization-time-of-flight mass spectrometry and could be further refined with specific PCR.

Implications:

  • This finding expands the known spectrum of P. apista infections beyond the pulmonary system.
  • Accurate diagnosis and prompt antibiotic treatment are crucial for managing this rare opportunistic CNS infection.
  • The case underscores the importance of considering unusual pathogens in complex infections, even in non-CF patients.